Entropy Technologies LP Has $1.80 Million Stake in Arrowhead Pharmaceuticals, Inc. $ARWR

Entropy Technologies LP boosted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 159.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,139 shares of the biotechnology company’s stock after purchasing an additional 16,666 shares during the period. Entropy Technologies LP’s holdings in Arrowhead Pharmaceuticals were worth $1,802,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. M&T Bank Corp increased its holdings in Arrowhead Pharmaceuticals by 2,569.6% during the 4th quarter. M&T Bank Corp now owns 240,634 shares of the biotechnology company’s stock valued at $15,976,000 after purchasing an additional 231,620 shares in the last quarter. Erste Asset Management GmbH increased its holdings in Arrowhead Pharmaceuticals by 55.3% during the 3rd quarter. Erste Asset Management GmbH now owns 73,000 shares of the biotechnology company’s stock valued at $2,466,000 after purchasing an additional 26,000 shares in the last quarter. Fisher Asset Management LLC increased its holdings in Arrowhead Pharmaceuticals by 133.3% during the 3rd quarter. Fisher Asset Management LLC now owns 1,053,794 shares of the biotechnology company’s stock valued at $36,345,000 after purchasing an additional 602,139 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Arrowhead Pharmaceuticals by 90.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 775,717 shares of the biotechnology company’s stock valued at $26,754,000 after buying an additional 368,073 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Arrowhead Pharmaceuticals by 3.1% in the 3rd quarter. Rhumbline Advisers now owns 371,112 shares of the biotechnology company’s stock valued at $12,800,000 after buying an additional 11,115 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 10,000 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This trade represents a 4.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total value of $934,328.25. Following the completion of the transaction, the chief financial officer owned 162,905 shares in the company, valued at $11,623,271.75. This represents a 7.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 26,065 shares of company stock worth $1,912,662 in the last three months. Insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Up 3.5%

NASDAQ:ARWR opened at $77.15 on Tuesday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $14.30 and a 12-month high of $82.26. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. The firm has a market capitalization of $10.87 billion, a P/E ratio of -35.88 and a beta of 1.28. The stock’s fifty day simple moving average is $72.78 and its 200-day simple moving average is $67.08.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The business had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. During the same period last year, the company earned $2.75 EPS. The firm’s revenue was down 86.4% on a year-over-year basis. Equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on ARWR shares. Sanford C. Bernstein increased their price objective on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Royal Bank Of Canada increased their price objective on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Morgan Stanley upgraded Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $78.00 to $100.00 in a research report on Tuesday, April 21st. Wall Street Zen lowered Arrowhead Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $87.80.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.